CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 11862185.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite cutaneous B-cell lymphoma often having a relatively indolent course and low mortality, it is often resistant to conventional therapy and frequently relapses. We describe a patient with widespread cutaneous B-cell lymphoma who was treated successfully with a recently approved chimeric monoclonal antibody directed against the CD20 antigen (rituximab) and the CD20-negative relapse that resulted.
Medical subject headings
- Antibodies, Monoclonal
- Antigens, CD20
- Antineoplastic Agents
- Lymphoma, B-Cell
- Skin Neoplasms